219 related articles for article (PubMed ID: 34635587)
1. The Role of Properdin in C5 Convertase Activity and C5b-9 Formation in the Complement Alternative Pathway.
Michels MAHM; Maas RJF; van der Velden TJAM; van de Kar NCAJ; van den Heuvel LPWJ; Volokhina EB;
J Immunol; 2021 Nov; 207(10):2465-2472. PubMed ID: 34635587
[TBL] [Abstract][Full Text] [Related]
2. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
DiScipio RG
Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
[TBL] [Abstract][Full Text] [Related]
3. Properdin and complement activation: a fresh perspective.
Hourcade DE
Curr Drug Targets; 2008 Feb; 9(2):158-64. PubMed ID: 18288967
[TBL] [Abstract][Full Text] [Related]
4. Initial properdin binding contributes to alternative pathway activation at the surface of viable and necrotic cells.
van Essen MF; Schlagwein N; van den Hoven EMP; van Gijlswijk-Janssen DJ; Lubbers R; van den Bos RM; van den Born J; Ruben JM; Trouw LA; van Kooten C;
Eur J Immunol; 2022 Apr; 52(4):597-608. PubMed ID: 35092629
[TBL] [Abstract][Full Text] [Related]
5. Studies on the mechanism of bacterial resistance to complement-mediated killing. VI. IgG increases the bactericidal efficiency of C5b-9 for E. coli 0111B4 by acting at a step before C5 cleavage.
Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
J Immunol; 1983 Nov; 131(5):2570-5. PubMed ID: 6355297
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the stabilization of the complement alternative pathway C3 convertase by properdin.
Alcorlo M; Tortajada A; Rodríguez de Córdoba S; Llorca O
Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13504-9. PubMed ID: 23901101
[TBL] [Abstract][Full Text] [Related]
7. Formation of high-affinity C5 convertases of the alternative pathway of complement.
Rawal N; Pangburn M
J Immunol; 2001 Feb; 166(4):2635-42. PubMed ID: 11160326
[TBL] [Abstract][Full Text] [Related]
8. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
Hammer CH; Hänsch G; Gresham HD; Shin ML
J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
[TBL] [Abstract][Full Text] [Related]
9. Surface-dependent modulation by H of C5 cleavage by the cell-bound alternative pathway C5 convertase of human complement.
Fischer E; Kazatchkine MD
J Immunol; 1983 Jun; 130(6):2821-4. PubMed ID: 6222117
[TBL] [Abstract][Full Text] [Related]
10. Serum properdin consumption as a biomarker of C5 convertase dysregulation in C3 glomerulopathy.
Corvillo F; Bravo García-Morato M; Nozal P; Garrido S; Tortajada A; Rodríguez de Córdoba S; López-Trascasa M
Clin Exp Immunol; 2016 Apr; 184(1):118-25. PubMed ID: 26660535
[TBL] [Abstract][Full Text] [Related]
11. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
Fishelson Z; Müller-Eberhard HJ
J Immunol; 1984 Mar; 132(3):1425-9. PubMed ID: 6229580
[TBL] [Abstract][Full Text] [Related]
12. The cytolytic C5b-9 complement complex: feedback inhibition of complement activation.
Bhakdi S; Maillet F; Muhly M; Kazatchkine MD
Proc Natl Acad Sci U S A; 1988 Mar; 85(6):1912-6. PubMed ID: 3162317
[TBL] [Abstract][Full Text] [Related]
13. Functional Characterization of Alternative and Classical Pathway C3/C5 Convertase Activity and Inhibition Using Purified Models.
Zwarthoff SA; Berends ETM; Mol S; Ruyken M; Aerts PC; Józsi M; de Haas CJC; Rooijakkers SHM; Gorham RD
Front Immunol; 2018; 9():1691. PubMed ID: 30083158
[TBL] [Abstract][Full Text] [Related]
14. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
15. Bacterial killing by complement requires membrane attack complex formation via surface-bound C5 convertases.
Heesterbeek DA; Bardoel BW; Parsons ES; Bennett I; Ruyken M; Doorduijn DJ; Gorham RD; Berends ET; Pyne AL; Hoogenboom BW; Rooijakkers SH
EMBO J; 2019 Feb; 38(4):. PubMed ID: 30643019
[TBL] [Abstract][Full Text] [Related]
16. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism of complement inhibition unmasked by a tick salivary protein that binds to properdin.
Tyson KR; Elkins C; de Silva AM
J Immunol; 2008 Mar; 180(6):3964-8. PubMed ID: 18322205
[TBL] [Abstract][Full Text] [Related]
18. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
19. Functional and structural insight into properdin control of complement alternative pathway amplification.
Pedersen DV; Roumenina L; Jensen RK; Gadeberg TA; Marinozzi C; Picard C; Rybkine T; Thiel S; Sørensen UB; Stover C; Fremeaux-Bacchi V; Andersen GR
EMBO J; 2017 Apr; 36(8):1084-1099. PubMed ID: 28264884
[TBL] [Abstract][Full Text] [Related]
20. Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway.
Krisinger MJ; Goebeler V; Lu Z; Meixner SC; Myles T; Pryzdial EL; Conway EM
Blood; 2012 Aug; 120(8):1717-25. PubMed ID: 22802338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]